# Table of contents

**Chapter 1** General introduction and thesis outline 9

**PART 1 Clinical impact and current practice of CSF biomarkers**

**Chapter 2** The cerebrospinal fluid ‘Alzheimer profile’: easily said, but what does it mean? 21

**Chapter 3** Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic 43
*Alzheimers Dement.* 2014 August; e-publication ahead of print.

**Chapter 4** Performance and complications of lumbar puncture in memory clinics: results of a multicenter study 63
*Alzheimers Dement, under review.*

**PART 2 Heterogeneity of AD and new perspectives beyond amyloid**

**Chapter 5** APOE genotype modifies the predictive value of CSF biomarkers in preclinical Alzheimer’s Disease 89
*Alzheimers Dement, submitted.*

**Chapter 6** Increase in CSF F₂-isoprostanes is related to cognitive decline in APOE4 carriers 105

**Chapter 7** Matrix metalloproteinases in Alzheimer’s disease and effects of concurrent cerebral amyloid angiopathy 119
*J. Alzheimers Dis., under review.*

**Chapter 8** Cerebrospinal fluid levels of the synaptic protein neurogranin correlate with cognitive decline in prodromal Alzheimer’s disease 137
*Alzheimers Dement, 2014 December; e-publication ahead of print.*

**Chapter 9** Summary and general discussion 167

**Chapter 10** Nederlandse samenvatting 189

List of abbreviations 195
List of author affiliations 196
Theses of the VUmc Alzheimer center 199
Dankwoord 201
About the author 205
List of publications 206